Skip to main content
CGTX
NASDAQ Life Sciences

Cognition Therapeutics Advances Zervimesine for Dementia with Lewy Bodies Psychosis Following Positive FDA Meeting Minutes

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.08
Mkt Cap
$96.219M
52W Low
$0.222
52W High
$3.83
52W Position info
386% above low
Off High info
72% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

CGTX has more than doubled off its 52-week low of $0.222.

Summary

Cognition Therapeutics announced plans to advance zervimesine for dementia with Lewy bodies (DLB) psychosis, a condition with no approved treatments, following positive feedback from a Type C meeting with the FDA.


Key Events · Product Development and Regulatory · CGTX

  • Advancing Zervimesine for DLB Psychosis

    Cognition Therapeutics announced plans to advance the development of zervimesine for the treatment of dementia with Lewy bodies (DLB) psychosis, which affects up to 75% of patients.

  • Positive FDA Type C Meeting Outcome

    This decision follows the receipt of final minutes from a Type C meeting with the FDA, indicating a favorable regulatory strategy to expedite development.

  • Strong Phase 2 SHIMMER Data

    The company's strategy is supported by robust Phase 2 'SHIMMER' data, which demonstrated an 86% slowing of decline on the 12-item neuropsychiatric inventory (NPI-12) versus placebo.

  • Addresses Unmet Medical Need

    There are no approved medications for DLB psychosis, and traditional antipsychotics are often poorly tolerated or contraindicated, highlighting a significant unmet need that zervimesine aims to address.


Analysis · CGTX · Life Sciences

This filing details Cognition Therapeutics' decision to advance zervimesine for dementia with Lewy bodies (DLB) psychosis, a significant step for a clinical-stage biopharmaceutical company. The move is based on positive feedback from a Type C meeting with the FDA and strong Phase 2 'SHIMMER' data, which showed an 86% slowing of decline in neuropsychiatric symptoms. This is particularly impactful as there are currently no approved medications for DLB psychosis, and existing antipsychotics are often contraindicated, highlighting a substantial unmet medical need. The company's plan to pursue a registrational path and meet with the FDA Division of Psychiatry by midyear 2026 suggests an expedited development timeline, which could significantly de-risk the program and provide a clear path to market for a potentially critical treatment.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CGTX was trading at $1.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $96.2M. The 52-week trading range was $0.22 to $3.83. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CGTX - Latest Insights

CGTX
Nov 05, 2026, 6:15 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.6833
Real-time Price: $0.580 info
Change: -$0.1033 (-15%) info
Market Cap: $55.368M info
CGTX
Nov 05, 2026, 6:04 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.6833
Real-time Price: $0.580 info
Change: -$0.1033 (-15%) info
Market Cap: $55.368M info
CGTX
Oct 22, 2026, 6:06 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.800
Real-time Price: $0.580 info
Change: -$0.220 (-28%) info
Market Cap: $55.368M info
CGTX
Oct 22, 2026, 6:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.7995
Real-time Price: $0.580 info
Change: -$0.2195 (-27%) info
Market Cap: $55.368M info
CGTX
Oct 13, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.865
Real-time Price: $0.580 info
Change: -$0.285 (-33%) info
Market Cap: $55.368M info